Deep understanding of the cell types and immune circuits relevant to HLH-like toxicity.
Creative Biolabs has a tradition of commitment. To achieve efficient execution and regulatory approval, we offer careful considerations of your program for the development of a cellular or gene therapy product – now and in the future.
EXPLORE MORE HighlightsWe focus on unmet needs and develop novel cellular and gene drugs and solutions that offer significant benefits over existing options.
EXPLORE MORE HighlightsThe advent of Chimeric Antigen Receptor T-cell (CAR-T) therapies has revolutionized the field of oncology, providing new avenues for treating various forms of cancer. Our 20 years of experience in the biotechnology sector have equipped us with the expertise and technological capabilities to support the entire lifecycle of CAR-T products, from early development to commercialization.
EXPLORE MORETo accelerate advanced breakthroughs of your projects, we offer broad range of platforms which enable our clients be free to tackle problems with cutting-edge technologies from different angles and in different methods.
EXPLORE MORE HighlightsUse the resources in our library to help you understand your options and make critical decisions for your study. We offer oncolytic virus, CAR-T, and dendritic cell related documents, as well as newsletter. If you don't find the answers you're looking for, contact us for additional assistance.
EXPLORE MORE HighlightsGet a real taste and understanding of the business and culture of one of the world's great research-based cellular and gene therapy discovery and development companies.
EXPLORE MORE
Immune effector cell-associated HLH-like syndrome (IEC-HS) represents a hyperinflammatory immune dysregulation event triggered by intensive cellular activation in the context of adoptive immunotherapy, such as CAR-T cell administration. While cytokine profiling offers a snapshot of soluble inflammatory mediators, comprehensive characterization of cellular actors—particularly the phenotypic status of innate and adaptive immune cells—is essential for understanding the initiation, propagation, and resolution of HLH-like cascades.
Creative Biolabs offers a dedicated IEC-HS Immunophenotyping Service designed to unravel the dynamic cellular landscape underlying IEC-HS, providing insight into immune activation signatures, cellular exhaustion, myeloid skewing, and lymphoid subset imbalances through high-dimensional and customized flow cytometry platforms.
Our service enables multiparametric immunophenotyping of immune populations involved in IEC-HS-like immune overactivation, using validated antibody panels and optimized protocols across human and murine systems. The service is compatible with a variety of sample sources and experimental models.
Deep understanding of the cell types and immune circuits relevant to HLH-like toxicity.
Tailored for specific CAR constructs, animal models, or intervention strategies.
Supports both in vitro and in vivo studies, including longitudinal immune monitoring.
Ability to detect subtle activation shifts and rare populations driving inflammatory dysregulation.
Results contextualized within the broader IEC-HS toxicity mechanism framework.
Q1: Can you help design a panel specific to my CAR construct?
A1: Yes. We routinely design panels to reflect the signaling architecture and immune consequences of specific CAR designs.
Q2: Do you offer murine-compatible immunophenotyping?
A2: Absolutely. We offer fully validated mouse antibody panels, including Ly6C/G, CD11b, F4/80, and others relevant to HLH-like responses.
Q3: What is the minimum sample size required?
A3: Typically, 0.5–1 million viable cells per sample are sufficient for standard panels; fewer may suffice depending on targets.
Q4: Do you provide downstream integration with cytokine data?
A4: Yes. Our services are modular but interoperable—we can correlate cellular phenotypes with soluble cytokine profiles from the same sample set.
Creative Biolabs brings together advanced cytometry technology, immune mechanistic expertise, and customized experimental design to support your IEC-HS research. Our Immunophenotyping Service empowers you to dissect cellular contributors to HLH-like immune perturbations and enables precise modeling of immunotoxic events in CAR-T development pipelines.
Let us help you reveal the cellular fingerprint of IEC-HS.
For any technical issues or product/service related questions, please leave your information below. Our team will contact you soon.
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
NEWSLETTER
The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders
LEARN MORE NEWSLETTER
NEW SOLUTION
CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.
LEARN MORE SOLUTION
NOVEL TECHNOLOGY
Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.
LEARN MORE NOVEL TECHNOLOGY
NEW SOLUTION
Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.
LEARN MORE SOLUTION
